MeiraGTx (MGTX) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MeiraGTx (MGTX) has outperformed Vor Biopharma (VOR) over the past year, gaining 27.4% versus a loss of 44.4%. Over five years, MGTX leads with a -24.2% price change compared with -93.9% for VOR. Vor Biopharma is the larger company by market cap ($1.11 billion vs $1.04 billion), about 1.1 times the size.
On valuation, Vor Biopharma trades at a lower trailing P/E (0.1x vs 12.4x for MeiraGTx).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGTX | VOR |
|---|---|---|
| Share price | $10.82 | $18.78 |
| Market cap | $1.04B | $1.11B |
| 1-day change | +2.08% | +2.57% |
| YTD return | +36.10% | +43.58% |
| 1-year return | +27.44% | -44.44% |
| 5-year return | -24.23% | -93.93% |
| P/E ratio (TTM) | 12.44 | 0.10 |
| EPS (TTM) | $0.87 | $180.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.35 | $33.50 |
| 52-week low | $6.62 | $6.50 |
| Distance from 52-week high | -29.51% | -43.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +156.47% | +107.67% |
| Average volume | 797.37K | 992.56K |
| Shares outstanding | 96.04M | 59.16M |
| Employees | 393 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGTX has outperformed VOR by 71.9 percentage points over the past year.
- MeiraGTx trades at a higher earnings multiple (12.4x vs 0.1x trailing P/E).
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
MGTX vs VOR FAQ
Which is bigger, MeiraGTx or Vor Biopharma?
Vor Biopharma (VOR) is larger, with a market capitalization of $1.11B compared with $1.04B for MeiraGTx (MGTX).
Which stock has performed better over the past year, MGTX or VOR?
MGTX returned +27.44% over the past 12 months, compared with -44.44% for VOR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, MGTX or VOR?
VOR has the lower trailing P/E at 0.1, versus 12.4 for MGTX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are MeiraGTx and Vor Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.